Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhibition of HBV Transcription From cccDNA With Nitazoxanide by Targeting the HBx–DDB1 Interaction
Kazuma Sekiba, Motoyuki Otsuka, Motoko Ohno, et al.
Cellular and Molecular Gastroenterology and Hepatology (2018) Vol. 7, Iss. 2, pp. 297-312
Open Access | Times Cited: 101

Showing 1-25 of 101 citing articles:

Therapeutic strategies for hepatitis B virus infection: towards a cure
Gregory Fanning, Fabien Zoulim, Jinlin Hou, et al.
Nature Reviews Drug Discovery (2019) Vol. 18, Iss. 11, pp. 827-844
Closed Access | Times Cited: 466
Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡
Markus Cornberg, Anna Suk‐Fong Lok, Norah A. Terrault, et al.
Journal of Hepatology (2019) Vol. 72, Iss. 3, pp. 539-557
Open Access | Times Cited: 291
Hepatitis B virus biology and life cycle
Senko Tsukuda, Koichi Watashi
Antiviral Research (2020) Vol. 182, pp. 104925-104925
Open Access | Times Cited: 259
Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections
María Guadalupe Martínez, Anders Boyd, Emmanuel Combe, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 3, pp. 706-717
Open Access | Times Cited: 109
Hepatitis B Viral Protein HBx and the Molecular Mechanisms Modulating the Hallmarks of Hepatocellular Carcinoma: A Comprehensive Review
Enakshi Sivasudhan, Neil Blake, Zhi-Liang Lu, et al.
Cells (2022) Vol. 11, Iss. 4, pp. 741-741
Open Access | Times Cited: 82
Protein neddylation and its role in health and diseases
Shizhen Zhang, Qing Yu, Zhijian Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 36
The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus
Luke D. Jasenosky, Cristhian Cadena, Chad E. Mire, et al.
iScience (2019) Vol. 19, pp. 1279-1290
Open Access | Times Cited: 128
Medicinal chemistry strategies toward host targeting antiviral agents
Xingyue Ji, Zhuorong Li
Medicinal Research Reviews (2020) Vol. 40, Iss. 5, pp. 1519-1557
Open Access | Times Cited: 94
Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?
Dina B. Mahmoud, Zayyanu Shitu, Ahmed Mostafa
Journal of Genetic Engineering and Biotechnology (2020) Vol. 18, Iss. 1, pp. 35-35
Open Access | Times Cited: 94
Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL‐AASLD HBV Treatment Endpoints Conference
Markus Cornberg, Anna Suk‐Fong Lok, Norah A. Terrault, et al.
Hepatology (2019) Vol. 71, Iss. 3, pp. 1070-1092
Open Access | Times Cited: 89
Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy
Rong Fan, Bin Zhou, Min Xu, et al.
Clinical Gastroenterology and Hepatology (2019) Vol. 18, Iss. 3, pp. 719-727.e7
Open Access | Times Cited: 87
Can we cure hepatitis B virus with novel direct‐acting antivirals?
María Guadalupe Martínez, François Villeret, Barbara Testoni, et al.
Liver International (2020) Vol. 40, Iss. S1, pp. 27-34
Closed Access | Times Cited: 71
Relevance of HBx for Hepatitis B Virus-Associated Pathogenesis
Anja Schollmeier, Mirco Glitscher, Eberhard Hildt
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4964-4964
Open Access | Times Cited: 34
Cryptosporidium uses CSpV1 to activate host type I interferon and attenuate antiparasitic defenses
Silu Deng, Wei He, Ai‐Yu Gong, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 24
The progress of molecules and strategies for the treatment of HBV infection
Youlu Pan, Heye Xia, Yanwen He, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 23
HBx protein as a therapeutic target for functional cure of hepatitis B virus infection
Vijay Kumar
Virology (2025) Vol. 604, pp. 110438-110438
Closed Access | Times Cited: 1
HBx-induced degradation of Smc5/6 complex impairs homologous recombination-mediated repair of damaged DNA
Kazuma Sekiba, Motoyuki Otsuka, Kazuyoshi Funato, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 1, pp. 53-62
Open Access | Times Cited: 54
Eliminating cccDNA to cure hepatitis B virus infection
Fabien Zoulim, Barbara Testoni
Journal of Hepatology (2023) Vol. 78, Iss. 4, pp. 677-680
Open Access | Times Cited: 17
Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives
Janitha M. Unagolla, Subarna Das, Riley Flanagan, et al.
International Journal of Pharmaceutics (2024) Vol. 660, pp. 124381-124381
Closed Access | Times Cited: 6
Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?
Andrew V. Stachulski, Joshua Taujanskas, Sophie Pate, et al.
ACS Infectious Diseases (2020) Vol. 7, Iss. 6, pp. 1317-1331
Open Access | Times Cited: 46
Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors
Wei-Chung Chiou, Meng-Shiuan Hsu, Yun‐Ti Chen, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2021) Vol. 36, Iss. 1, pp. 147-153
Open Access | Times Cited: 40
Hepatitis B virus–host interactions and novel targets for viral cure
Gaëtan Ligat, Éloi R. Verrier, Michael Nassal, et al.
Current Opinion in Virology (2021) Vol. 49, pp. 41-51
Open Access | Times Cited: 39
Current Progress in the Development of Hepatitis B Virus Capsid Assembly Modulators: Chemical Structure, Mode-of-Action and Efficacy
Hyejin Kim, Chunkyu Ko, Joo‐Youn Lee, et al.
Molecules (2021) Vol. 26, Iss. 24, pp. 7420-7420
Open Access | Times Cited: 35
Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure
Efthymios P. Tsounis, Evanthia Tourkochristou, Αthanasia Mouzaki, et al.
World Journal of Gastroenterology (2021) Vol. 27, Iss. 21, pp. 2727-2757
Open Access | Times Cited: 34
Hepatitis B Virus DNA Integration and Clonal Expansion of Hepatocytes in the Chronically Infected Liver
William S. Mason, Allison R. Jilbert, Samuel Litwin
Viruses (2021) Vol. 13, Iss. 2, pp. 210-210
Open Access | Times Cited: 33
Page 1 - Next Page

Scroll to top